Wells Fargo Says Outside Interest in Multiple Myeloma Space a Positive for Array Biopharma

by Benzinga Staff
July 1, 2013 2:48 PM | 20 seconds read

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.

Array Biopharma (NASDAQ: ARRY) shares are up over 5 percent in Monday's afternoon session as the earlier Amgen (NASDAQ: AMGN), Onyx (NASDAQ: ONXX) bid and the Celgene (NASDAQ: CELG) MorphoSys partnership signals significant interest in the multiple myeloma space, according to Wells Fargo's Matthew Andrews.The analyst believes Array's ARRY-520 is an under-appreciated asset in this field.Andrews maintains an Outperform rating on shares of Array Biopharma.

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: Analyst ColorAnalyst Ratings

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.